Related Experiment Video
Updated: May 3, 2026
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
3.6K
IPX066: a new intermediate-and extended-release carbidopa-levodopa formulation
1Center for Neurodegeneration & Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA; and Civitan International Research Center 560D, 1719 6th Avenue South, Birmingham, AL 35294, USA; Tel.: +1 205 996 7543; ; tyacoub@uab.edu.
Neurodegenerative Disease Management
|February 7, 2014
Summary
New Carbidopa-levodopa (CD-LD) formulations aim to reduce Parkinson's disease (PD) motor fluctuations. IPX066, a novel CD-LD, shows improved effectiveness in advanced PD, reducing
Area of Science:
- Neurology
- Pharmacology
- Movement Disorders
Background:
- Carbidopa-levodopa (CD-LD) is the primary treatment for Parkinson's disease (PD).
- Motor fluctuations are common in advanced PD patients on CD-LD therapy.
- Developing extended-release CD-LD formulations is crucial for managing motor fluctuations.
Purpose of the Study:
- To evaluate the efficacy of IPX066, a novel CD-LD formulation, in patients with advanced Parkinson's disease.
- To compare the effectiveness of IPX066 against existing CD-LD formulations.
- To assess the potential role of IPX066 in early Parkinson's disease.
Main Methods:
- Clinical trials were conducted to assess IPX066's effectiveness.
- IPX066 combines immediate-release and sustained-release levodopa components.
- Patient outcomes, including 'off' time, were measured and compared.
Main Results:
- IPX066 demonstrated improved effectiveness in advanced PD compared to other CD-LD formulations.
- A significant reduction in 'off' time (approximately 37%) was observed with IPX066.
- IPX066 showed efficacy in early PD when compared to placebo.
Conclusions:
- IPX066 represents a promising advancement in managing motor fluctuations in advanced PD.
- The novel formulation offers a potential therapeutic option for patients experiencing motor fluctuations.
- Further research is needed to clarify IPX066's role in early PD relative to other treatments.
Related Concept Videos
01:26Oral Drug Delivery Systems: Continuous-Release Systems
308
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
308
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
137
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
137
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
172
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
172
01:19Modified-Release Drug Delivery Systems: Overview
236
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
236
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
257
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
257
01:24Modified-Release Drug Delivery Systems: Site-Targeted
164
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
164